Php277 - How Do Bellwether Hta Agencies Evaluate Biosimilars?

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1171
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

How Do Swedish Government Agencies Define Risk?

Journal of Risk Research
ManagementRiskStrategyEngineeringReliabilitySafetyQualitySocial Sciences
2018English

Bridging HTA Agencies Across Europe: A Systematic Approach to Categorize Evolving Agencies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Reimbursement Decision Landscape for Orphan Drugs Across Six Hta Agencies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

How Do Learners Perceive and Evaluate Their Digital Skills?

International Journal of Smart Education and Urban Society
2018English

Pcn275 - How Do Hta Decisions for New Disease Conditions Impact Time to Price Changes?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy185 - Alternative Methodologies Implemented by Hta Agencies for Orphan Drugs: A Scoping Review

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Biosimilars: How Can Payers Get Long-Term Savings?

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2016English

How Do We Evaluate the Learning of History? Experiences and Considerations

Revista Digital Universitaria
2018English

Biosimilars: What Do Patients Need to Consider?

RMD Open
RheumatologyAllergyImmunology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy